CJM 112

Drug Profile

CJM 112

Alternative Names: CJM112

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne; Hidradenitis suppurativa
  • Phase I/II Plaque psoriasis
  • Phase I Solid tumours
  • Preclinical Multiple sclerosis

Most Recent Events

  • 22 Mar 2017 Novartis plans a phase I trial of CJM 112 alone and of CJM 112 or LCL 161 in combination with PDR 001 for Multiple myeloma (Second-line therapy) (NCT03111992)
  • 07 Dec 2016 Phase-II clinical trials in Acne (In adults, In adolescents) in Netherlands (SC) (EudraCT2016-002492-95)
  • 01 Nov 2016 Novartis completes a phase II trial for Hidradenitis suppurativa in USA, Netherlands, Denmark, Germany and Switzerland (NCT02421172)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top